Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

The U.S. Food and Drug Administration (FDA) has expanded the use of Modernas (NASDAQ:MRNA) RSV vaccine, mRESVIA, to adults aged 18 to 59 who are at increased risk of respiratory syncytial virus (RSV) ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

Scientists and analysts express concern that the newly appointed members—which include known anti-vaxxers—could relitigate ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

RSV monoclonal antibody, clesrovimab,” which was approved by the FDA yesterday, Leerink Partners LLC analyst Daina Graybosch said. Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial ...

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...